医学
液体活检
肺癌
循环肿瘤DNA
癌症
疾病
肿瘤科
微小残留病
基因检测
重症监护医学
分子诊断学
靶向治疗
生物信息学
内科学
生物
白血病
作者
Ting-Hui Wu,Emily Han-Chung Hsiue,James Chih‐Hsin Yang
标识
DOI:10.1016/j.ctrv.2019.07.002
摘要
Current classification and treatment of lung cancer rely increasingly on molecular and genetic testing. Obtaining tumor tissue is not always feasible and multiple biopsies are undesirable. In response to the demand for non-invasive molecular and genetic testing in cancer care, several liquid biopsy technologies, including circulating DNA (ctDNA), have been developed. ctDNA analysis is now technically feasible to be carried out in large scales and integrated into clinical practice owing to the advances in technology. Despite the challenges in improving test accuracy and cost-effectiveness, there are huge potentials for ctDNA analysis in lung cancer management. This review focuses on the clinical utility of ctDNA analysis in lung cancer, including early detection, monitoring treatment response and detecting residual disease, identification of genetic determinants for targeted therapy, and predicting efficacy of immune checkpoint blockade.
科研通智能强力驱动
Strongly Powered by AbleSci AI